

## **U.K. Erectile Dysfunction Market - Industry Trends and Forecast to 2031**

Market Report | 2024-03-01 | 106 pages | Data Bridge Market Research

### **AVAILABLE LICENSES:**

- Single User License \$3500.00
- Corporate Users License \$4200.00

### **Report description:**

U.K. erectile dysfunction market is expected to reach USD 451.63 million by 2031, from USD 260.49 thousand in 2023 growing at the CAGR of 7.2% in the forecast period of 2024 to 2031.

#### Market Segmentation

U.K. Erectile Dysfunction Market, By Product Type (Drugs and Devices), Type (Secondary Erectile Dysfunction and Primary Erectile Dysfunction), Age Group (Less than 40, 40-60 and 60 - Above), End User (Hospital, Specialty Clinics, Home Healthcare, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tenders, Retail Pharmacy, Online Pharmacy, Hospital Pharmacy and Others) - Industry Trends and Forecast to 2031

Overview of U.K. Erectile Dysfunction Market Dynamics

#### Driver

- Rising prevalence of chronic diseases

#### Restraint

- Regulatory constraints for approval

#### Opportunity

- Availability of prescription medication and its generic version

#### Market Players

Some of the key market players for U.K. erectile dysfunction market are:

- Lupin
- Teva Pharmaceutical Industries Ltd.
- Augusta Medical Systems
- Boston Scientific Corporation
- Coloplast Corp
- Rigicon, Inc.
- Pfizer Inc.
- Bayer AG
- Eli Lilly and Company

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- Viatris Inc.
- ZSI, Zephyr Surgical Implants

## **Table of Contents:**

### TABLE OF CONTENTS

1 INTRODUCTION	11
1.1 OBJECTIVES OF THE STUDY	11
1.2 MARKET DEFINITION	11
1.3 OVERVIEW OF U.K. ERECTILE DYSFUNCTION MARKET	11
1.4 CURRENCY AND PRICING	12
1.5 LIMITATIONS	12
1.6 MARKETS COVERED	13
2 MARKET SEGMENTATION	15
2.1 MARKETS COVERED	15
2.2 GEOGRAPHICAL SCOPE	16
2.3 YEARS CONSIDERED FOR THE STUDY	16
2.4 DBMR TRIPOD DATA VALIDATION MODEL	17
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	20
2.6 MULTIVARIATE MODELLING	21
2.7 MARKET END USER COVERAGE GRID	22
2.8 PRODUCT LIFELINE CURVE	23
2.9 DBMR MARKET POSITION GRID	24
2.10 VENDOR SHARE ANALYSIS	25
2.11 SECONDARY SOURCES	26
2.12 ASSUMPTIONS	26
3 EXECUTIVE SUMMARY	27
4 PREMIUM INSIGHTS	29
4.1 PESTEL ANALYSIS	30
4.2 PORTER'S FIVE FORCES MODEL	31
4.3 VENDOR SHARE ANALYSIS	32
4.4 BRAND ANALYSIS	33
4.4.1 LEADING BRANDS	33
4.4.2 BRAND POSITIONING	33
4.4.3 MARKET PENETRATION	34
4.4.4 COMPETITIVE ANALYSIS	35
4.5 CONSUMER INSIGHTS	36
4.5.1 DEMOGRAPHIC INSIGHTS	36
4.5.2 PSYCHOGRAPHIC PROFILE	36
4.5.3 CONSUMER PREFERENCES	37
4.5.4 PURCHASING BEHAVIOUR	37
4.5.5 FACTORS INFLUENCING BUYING DECISION	37
4.6 PERFORMANCE ANALYSIS	39
4.6.1 TREND ANALYSIS	39
4.7 RETAIL ANALYSIS	41
5 MARKET OVERVIEW	44

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

5.1 DRIVERS	46
5.1.1 RISING PREVALENCE OF CHRONIC DISEASES	46
5.1.2 RISING ADOPTION OF SEDENTARY LIFESTYLE AND ASSOCIATED STRESS	46
5.1.3 RISING PRODUCT LAUNCHES BY MAJOR MARKET PLAYERS	47
5.1.4 RISING PATIENT AWARENESS REGARDING THE CONDITION AND MEDICATION	47
5.2 RESTRAINTS	48
5.2.1 REGULATORY CONSTRAINTS FOR APPROVAL	48
5.2.2 HIGH COST OF ERECTILE DYSFUNCTION TREATMENT	48
5.3 OPPORTUNITIES	49
5.3.1 AVAILABILITY OF PRESCRIPTION MEDICATION AND ITS GENERIC VERSION	49
5.3.2 RISING TECHNOLOGICAL ADVANCEMENTS	49
5.3.3 RISING RESEARCH AND DEVELOPMENT ACTIVITIES	50
5.4 CHALLENGES	51
5.4.1 VARIOUS SIDE EFFECTS ASSOCIATED WITH ERECTILE DYSFUNCTION DRUGS	51
5.4.2 LACK OF SKILLED PROFESSIONALS	51
6 U.K. ERECTILE DYSFUNCTION MARKET, BY PRODUCT TYPE	52
6.1 OVERVIEW	53
6.2 DRUGS	56
6.2.1 ORAL DRUGS	56
6.2.1.1 BRANDED	57
6.2.1.1.1 VIAGRA	57
6.2.1.1.2 CIALIS	57
6.2.1.1.3 LEVITRA	57
6.2.1.1.4 AVANAFIL	57
6.2.1.1.5 OTHERS	57
6.2.1.2 GENERIC	57
6.2.2 TOPICAL FORMULATION	58
6.2.3 PENILE INJECTIONS	58
6.2.3.1 PAPAVERINE	58
6.2.3.2 PHENTOLAMINE	58
6.2.3.3 PROSTAGLANDIN E1 (PGE1)	58
6.2.4 SUPPOSITORIES	58
?	
6.3 DEVICES	59
6.3.1 PENIS PUMPS/VACCUUM CONSTRICTION DEVICES	59
6.3.1.1 HAND-POWERED	59
6.3.1.2 BATTERY-POWERED PUMP	59
6.3.2 PENILE IMPLANTS	60
6.3.2.1 SEMIRIGID/MALLEABLE	60
6.3.2.2 INFLATABLE	60
6.3.3 SHOCK WAVE THERAPY	60
7 U.K. ERECTILE DYSFUNCTION MARKET, BY TYPE	61
7.1 OVERVIEW	62
7.2 SECONDARY ERECTILE DYSFUNCTION	65
7.3 PRIMARY ERECTILE DYSFUNCTION	65
8 U.K. ERECTILE DYSFUNCTION MARKET, BY AGE GROUP	66
8.1 OVERVIEW	67

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

8.2 LESS THAN 40	70
8.3 40-60	70
8.4 60 AND ABOVE	70
9 U.K. ERECTILE DYSFUNCTION MARKET, BY END USER	71
9.1 OVERVIEW	72
9.2 HOSPITALS	75
9.3 SPECIALTY CLINICS	75
9.4 HOME HEALTHCARE	75
9.5 AMBULATORY SURGICAL CENTERS	75
9.6 OTHERS	75
10 U.K. ERECTILE DYSFUNCTION MARKET, BY DISTRIBUTION CHANNEL	76
10.1 OVERVIEW	77
10.2 DIRECT TENDERS	80
10.3 HOSPITAL PHARMACY	80
10.4 RETAIL PHARMACY	80
10.5 ONLINE PHARMACY	80
10.6 OTHERS	80
11 U.K. ERECTILE DYSFUNCTION MARKET, COMPANY LANDSCAPE	81
11.1 COMPANY SHARE ANALYSIS: GLOBAL	81
12 SWOT ANALYSIS	82
?	
13 COMPANY PROFILES	83
13.1 PFIZER INC.	83
13.1.1 COMPANY SNAPSHOT	83
13.1.2 REVENUE ANALYSIS	83
13.1.3 PRODUCT PORTFOLIO	84
13.1.4 RECENT DEVELOPMENTS	84
13.2 LUPIN	85
13.2.1 COMPANY SNAPSHOT	85
13.2.2 REVENUE ANALYSIS	85
13.2.3 PRODUCT PORTFOLIO	86
13.2.4 RECENT DEVELOPMENTS	86
13.3 COLOPLAST CORP	87
13.3.1 COMPANY SNAPSHOT	87
13.3.2 REVENUE ANALYSIS	87
13.3.3 PRODUCT PORTFOLIO	88
13.3.4 RECENT DEVELOPMENTS	88
13.4 VIATRIS INC.	89
13.4.1 COMPANY SNAPSHOT	89
13.4.2 REVENUE ANALYSIS	89
13.4.3 PRODUCT PORTFOLIO	90
13.4.4 RECENT DEVELOPMENTS	90
13.5 TEVA PHARMACEUTICAL INDUSTRIES LTD.	91
13.5.1 COMPANY SNAPSHOT	91
13.5.2 REVENUE ANALYSIS	91
13.5.3 PRODUCT PORTFOLIO	92
13.5.4 RECENT DEVELOPMENTS	92

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

13.6	AUGUSTA MEDICAL SYSTEMS	93
13.6.1	COMPANY SNAPSHOT	93
13.6.2	PRODUCT PORTFOLIO	93
13.6.3	RECENT DEVELOPMENT	93
13.7	BAYER AG	94
13.7.1	COMPANY SNAPSHOT	94
13.7.2	REVENUE ANALYSIS	94
13.7.3	PRODUCT PORTFOLIO	95
13.7.4	RECENT DEVELOPMENTS	95
13.8	BOSTON SCIENTIFIC CORPORATION	96
13.8.1	COMPANY SNAPSHOT	96
13.8.2	REVENUE ANALYSIS	96
13.8.3	PRODUCT PORTFOLIO	97
13.8.4	RECENT DEVELOPMENTS	97
13.9	ELI LILY AND COMPANY	98
13.9.1	COMPANY SNAPSHOT	98
13.9.2	REVENUE ANALYSIS	98
13.9.3	PRODUCT PORTFOLIO	99
13.9.4	RECENT DEVELOPMENTS	99
13.10	RIGICON, INC.	100
13.10.1	COMPANY SNAPSHOT	100
13.10.2	PRODUCT PORTFOLIO	100
13.10.3	RECENT DEVELOPMENT	101
13.11	ZEPHYR SURGICAL IMPLANTS.	102
13.11.1	COMPANY SNAPSHOT	102
13.11.2	PRODUCT PORTFOLIO	102
13.11.3	RECENT DEVELOPMENT	102
14	QUESTIONNAIRE	103
15	RELATED REPORTS	106

## U.K. Erectile Dysfunction Market - Industry Trends and Forecast to 2031

Market Report | 2024-03-01 | 106 pages | Data Bridge Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-06"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com